Fig. 1.

Inhibition of Hsp70 by JG-98 re-sensitizes CRPC cells to ADT drugs in vitro and in vivo. A) Incucyte growth analysis of 22Rv1 CRPC cells in the presence of JG-98. B) Incucyte growth analysis of 22Rv1 CRPC cells in the presence of 150 nM JG-98 +/− 10 µM enzalutamide or abiraterone. C) Mean tumor volume (± SEM) of 22Rv1 xenografts in mice treated with vehicle (n = 7), JG-231 (6 mg/kg; n = 7), enzalutamide (ENZ) (25 mg/kg; n = 7), or combo (n = 7). D) Mean tumor volume (±SD) in mice treated with JG-231 or combo at day 37 (post-22Rv1 injection). Mice were removed from the study when tumor volume surpassed 1,800 mm³. Statistical significance determined by one-tailed unpaired t test.